Company: THRM
Filing Date: 2025-03-27
Form Type: DEF 14A
Source: 0001140361-25-010582
Chunk: 42

Company: Gentherm Inc
Filing Date: 2025-03-27
Form: DEF 14A
Chunk 42
---
 J. Runyon |   360,000 | 120,000 |   320,000 |   800,000 |
| Hui (Helen) Xu    |   405,000 | 135,000 |   360,000 |   900,000 |

The target values were divided by the 30-trading day average closing price of our common stock ending on the day immediately preceding the grant date to determine the number of target shares of PSUs and the actual number of RSUs awarded. The grant date for the awards to the NEOs was March 15, 2024, and the 30-trading day average closing price for our common stock ending on March 14, 2024 was $53.27. 67 | 2025 PROXY STATEMENT As a result, the number of target PSUs and actual RSUs awarded was as follows:

| Element | Target PSUS AdjustedEBITDA Margin(#) | Target PSUS RelativeRevenue Growth(#) | RSUS(#) |

| Phillip M. Eyler  | 44,350 | 14,783 | 25,344 |
| Matteo Anversa    | 14,361 |  4,787 | 12,768 |
| Thomas Stocker    |  7,603 |  2,534 |  6,759 |
| Jaymi Wilson      |  7,603 |  2,534 |  6,759 |
| Barbara J. Runyon |  6,758 |  2,253 |  6,009 |
| Hui (Helen) Xu    |  7,603 |  2,534 |  6,759 |

OBJECTIVE PSU ADJUSTMENT POLICY. The Committee adopts an objective policy each year concurrent with its approval of PSU awards to address the following unusual or extra-ordinary events (to the extent not already captured in the applicable definitions of the metrics), without limiting the Committee’s ability to apply adjustments in its discretion. The 2024 policy is set forth below:

| – | Adjusted EBITDA and Relative Revenue Growth.Adjusted EBITDA and Relative Revenue Growth goals (including threshold, target and maximum                                                                                               
 goals) and Adjusted EBITDA and Relative Revenue Growth achieved will be adjusted by the Committee to reflect the following items: acquisitions, investments and divestitures not addressed in the strategic plan for the performance 
 period; restructuring costs; regulatory changes